Savara (SVRA) “announced encore presentations of top-line data from the pivotal, Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP will be presented at the 65th Congress of the German Society of Pneumology in Leipzig, Germany taking place April 9-12 and at the 65th Annual Meeting of the Japanese Respiratory Society taking place April 11-3, 2025, in Tokyo, Japan.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA:
- Savara’s Strategic Advancements and Market Potential of Molbreevi: A Transformative Approach to aPAP Treatment
- Savara’s Strategic Positioning and Market Potential for Molbreevi in aPAP Treatment
- Savara reports Q4 EPS (13c), consensus (11c)
- Savara Secures $200 Million Loan Agreement with Hercules
- Savara completes BLA submission to FDA for Molbreevi